About Hemab
Hemab is a company based in Copenhagen (Denmark) founded in 2019. Hemab has raised $309.92 million across 4 funding rounds from investors including RA Capital, Deep Track Capital and Avoro Capital Advisors. The company has 10 employees as of December 31, 2022. Hemab offers products and services including HMB-001 and HMB-002. Hemab operates in a competitive market with competitors including Varmx, AbFero Pharmaceuticals, Alveron Pharma, TargED and Pangen Biotech, among others.
- Headquarter Copenhagen, Denmark
- Employees 10 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
-$22.15 M (USD)-345as on Dec 31, 2022
-
EBITDA
-$22.84 M (USD)-302as on Dec 31, 2022
-
Total Equity Funding
$309.92 M (USD)
in 4 rounds
-
Latest Funding Round
$157 M (USD), Series C
Oct 27, 2025
-
Investors
RA Capital
& 9 more
-
Employee Count
10
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Hemab
Hemab offers a comprehensive portfolio of products and services, including HMB-001 and HMB-002.
Antibody that stabilizes factor VIIa for bleeding disorder treatment
Antibody for preventing bleeding in Von Willebrand Disease
People of Hemab
Unlock access to complete
Unlock access to complete
Funding Insights of Hemab
Hemab has successfully raised a total of $309.92M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $157 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Hemab
Hemab has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include RA Capital, Deep Track Capital and Avoro Capital Advisors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Deep Track Capital is engaged in biotechnology investment activities.
|
Locked | Locked | Locked | |
|
Venture capital fund focused on biotechnology startups
|
Locked | Locked | Locked | |
|
Private equity investments are directed toward ESG-focused companies.
|
Locked | Locked | Locked |
Investor details for Hemab
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Hemab
Investment portfolio details for Hemab
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Hemab
Detailed financials for Hemab
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Hemab Comparisons
Peer comparison for Hemab
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Hemab
Hemab operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Varmx, AbFero Pharmaceuticals, Alveron Pharma, TargED and Pangen Biotech, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutic proteins are developed to restore blood clotting in patients.
|
|
| Locked | Locked | Locked |
Oral iron chelators are developed for iron overload disease treatment.
|
|
| Locked | Locked | Locked |
Drugs for haemorrhagic stroke and intracranial haemorrhage are developed.
|
|
| Locked | Locked | Locked |
Biological drugs for thrombosis treatment are developed by the company.
|
|
| Locked | Locked | Locked |
Developer of biosimilars and biologics
|
Detailed competitors of Hemab
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Hemab
Complete news archive for Hemab
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Hemab
Hemab was founded in 2019 and raised its 1st funding round 1 year after it was founded.
Hemab is headquartered in Copenhagen, Denmark.
Hemab is a funded company, having raised a total of $309.92M across 4 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Hemab is 10.
Hemab was founded in 2019 in Copenhagen, Denmark, within the biotechnology sector. Novel antibody-based therapies are developed by the company to modulate the bodys clotting pathway, either by stabilizing or inhibiting clotting factors. These treatments target unmet needs in rare bleeding and thrombotic disorders, with a pipeline of candidates aimed at prophylactic options and potential functional cures. Operations focus on addressing life-threatening complications for affected patients.
Hemab's top competitors include Varmx, Cadrenal Therapeutics and Alveron Pharma.
Hemab offers HMB-001 and HMB-002.
Hemab has 10 investors. Key investors include RA Capital, Deep Track Capital, Avoro Capital Advisors, Maj Invest, and Rock Springs Capital.